Supported and assisted by the GGBa, the U.S.-based company NeoGenomics has established its regional headquarters in Rolle, in the canton of Vaud. With a turnover of $250 million in 2016, the NASDAQ-listed multinational is a premier cancer diagnostics and pharma services company. Founded in 2001 in Florida, it employs 1,000 people in the United States and has now decided to tackle the European market.
The global market for clinical testing in the field of oncology is estimated at $2-3 billion. Europe represents about a quarter of this potential. It was therefore key for NeoGenomics to get a foothold in the old continent.
Tapping into the local talent pool
For its expansion in Europe, NeoGenomics was looking for a perfect site from a logistical point of view, with access to an exceptional talent pool. Located between Lausanne and Geneva and within close proximity to prestigious universities, the city of Rolle fulfills both conditions. The multinational will initially hire 14 people, and plans to increase its workforce to 50 employees, mainly locally recruited, in line with business development. "We do not plan to transfer U.S. expats permanently to Switzerland. If we second managers or researchers from our headquarters, it will be only temporarily, in order to kick off operations”, said the company's CFO, George Cardoza, to Swiss newspaper Le Temps.
